Table 5 Pim kinase inhibitors used in preclinical and clinical (bold) trials for MM
From: Targeting Pim kinases in hematological cancers: molecular and clinical review
Multiple Myeloma | Target | Type | Clinical Trials | |
|---|---|---|---|---|
IBL-202 | Pim/PI3K | Double inhibitor (PI3K, Pim) Monotherapy | Preclinical | – |
IBL-301 | Pim/PI3K/mTOR | Triple inhibitor (PI3K, mTOR, Pim) Monotherapy | Preclinical | – |
INCB053914 + pomalidomide + dexamethasone | pan-Pim + thalidomide analogue + corticosteroid | Triple-therapy | MM | NCT04355039 |
JP11646 | Pim2 | Single | Preclinical | – |
LGB321 | pan-Pim | Single | Preclinical | – |
LGB321 + BKM120 | pan-Pim + PI3K | Dual-therapy | Preclinical | – |
PIM447 | pan-Pim | Single | MM | NCT01456689 |
| Â | Â | Â | MM | NCT02144038 |
SGI-1776 | pan-Pim | Single | Yes | – |
Smi-16a | Pim1/Pim2 | Single | Preclinical | – |
Smi-16a + doxorubicin | Pim1/Pim2 + topoisomerase | Dual-therapy | – | – |
Uzansertib | pan-Pim | Single | MM | NCT04355039 |